IP Library Granted Patent US 9,802,976
Granted Patent B2
US 9,802,976 · App. 14/886,738 · Granted Oct 31, 2017

Method for preparing substituted 3,7-dihydroxy steroids

Inventors: Steven K. White (San Diego, CA); Yu Ge (San Diego, CA); Yujin Huang (San Diego, CA)
Assignee: NeurMedix, Inc.
C07J1/0048C07J71/00C07J75/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,802,976
App. No.
14/886,738
Granted
Oct 31, 2017
Kind
B2
Abstract

The invention relates to processes for preparing 17-alkynyl-7-hydroxy-steroids, such as 17-Ethynyl-10R,13S-dimethyl 2,3,4,7,8R,9S,10,11,12,13,14S,15,16,17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R,7R,17S-triol (also referred to as 17α-ethynyl-androst-5-ene-3β,7β,17β-triol), that are essentially free of process impurities having binding activity at nuclear estrogen receptors.

Claims (23)

1. A method to make 17α-ethynyl-androst-5-ene-3β,7β,17β-triol essentially free of steroid side-product lacking an oxygen substituent at position 7 comprising the steps of,

(a) contacting a compound having the structure

with a reducing agent to convert the ═O functional group at position 7 to hydroxy predominantly in the β-configuration wherein R 1 is —H, C 1-6 alkyl, C 3-6 cycloalkyl, optionally substituted aryl or optionally substituted heteroaryl and R 2 is C 1-6 alkyl or aryl;

(b) converting the ═NOR 2 group at position 17 in the reaction product from step (a) to a ═O group to obtain a 7β-hydroxy-17-one compound;

(c) converting the —OC(O)R 1 group at position 3 of the 7β-hydroxy-17-one compound to a 3β-hydroxy derivative of the 7β-hydroxy-17-one compound;

(d) converting the hydroxy groups at positions 3 and 7 in the 3β-hydroxy derivative of the 7β-hydroxy-17-one compound from step (c) to (R 3 ) 3 SiO— groups, wherein each R 3 independently is C 1-6 alkyl or aryl; and

(e) contacting the reaction product of step (d) with an compound having the structure of M-C≡C—Si(R 5 ) 3 , wherein R 5 independently are C 1-6 alkyl or aryl and M is a Group I, Group II or transition metal, wherein 17α-ethynyl-androst-5-ene-3β,7β,17β-triol essentially free of 17α-alkynyl-androst-5-ene-3β,17β-diol is obtained.

2. The method of claim 1 wherein R 1 is C 1-6 alkyl or phenyl.

3. The method of claim 2 wherein R 1 is —CH 3 .

4. The method of claim 2 wherein R 1 and R 2 are —CH 3 .

5. The method of claim 1 wherein M is Li, Mg or Zn.

6. The method of claim 1 wherein R 5 is —CH 3 .

7. The method of claim 1 wherein M is Li and R 5 is —CH 3 .

8. The method of claim 1 wherein comprising the additional step of purifying the 17α-ethynyl-androst-5-ene-3β,7β,17β-trial of step (e) by recrystallization.

9. The method of claim 8 wherein R 1 is —CH 3 .

10. The method of claim 8 wherein R 1 and R 2 are —CH 3 .

11. The method of claim 8 wherein M is Li, Mg or Zn.

12. The method of claim 8 wherein R 5 is —CH 3 .

13. The method of claim 8 wherein M is Li and R 5 is —CH 3 .

14. The method of claim 8 wherein the 17α-ethynyl-androst-5-ene-3β,7β,17β-triol of step (e) is purified by recrystallization from methanol-water.

15. The method of claim 14 wherein R 1 is —CH 3 .

16. The method of claim 14 wherein M is Li, Mg or Zn.

17. The method of claim 14 wherein R 5 is —CH 3 .

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: BIOVIE INC.
Reel/Frame 069510/0814 →
SECURITY INTEREST Recorded Dec 7, 2021
From: BIOVIE INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 058329/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2021
From: NEURMEDIX, INC.
To: NEURMEDIX, LLC
Reel/Frame 057123/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2021
From: NEURMEDIX, LLC
To: NEURMEDIX, INC.
Reel/Frame 057125/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2021
From: NEURMEDIX, INC.
To: BIOVIE INC.
Reel/Frame 057123/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2018
From: WHITE, STEVEN K.; GE, YU; HUANG, YUJIN
To: HOLLIS-EDEN PHARMACEUTICALS, INC.
Reel/Frame 046363/0014 →
CHANGE OF NAME Recorded Jan 29, 2016
From: HOLLIS-EDEN PHARMACEUTICALS, INC.
To: HARBOR BIOSCIENCES, INC.
Reel/Frame 037617/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2016
From: WHITE, STEVEN K; GE, YU; HUANG, YUJIN
To: HOLLIS-EDEN PHARMACEUTICALS, INC.
Reel/Frame 037651/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2016
From: RESERVA LLC
To: NEURMEDIX, INC.
Reel/Frame 037642/0724 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2016
From: HARBOR THERAPEUTICS, INC.
To: RESERVA LLC
Reel/Frame 037642/0639 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 29, 2016
From: HARBOR DIVERSIFIED, INC .
To: HARBOR THERAPEUTICS, INC.
Reel/Frame 037618/0495 →
MERGER AND CHANGE OF NAME Recorded Jan 29, 2016
From: HARBOR BIOSCIENCES, INC.; HARBOR DIVERSIFIED, INC .
To: HARBOR DIVERSIFIED, INC .
Reel/Frame 037618/0033 →
Continuity (6)
Division 12479626 · Jun 5, 2009
Continuation 13664304 · Oct 30, 2012
Division 12479626 · Jun 5, 2009
Division 14886738
Provisional Application 61059658 · Jun 6, 2008
Related Publication 20160039863A1 · Feb 11, 2016